

CURRICULUM VITAE

Jennifer Leigh Lund, PhD, MSPH

PERSONAL

Name: Jennifer Leigh Lund
Address: Department of Epidemiology
McGavran-Greenberg Hall, Suite 2102-D
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599-7435

Phone: 919-966-7440 (office)
Email: Jennifer.Lund@unc.edu

EDUCATION

Doctor of Philosophy (Epidemiology) 2009-2011
The University of North Carolina at Chapel Hill, Chapel Hill, NC

Master of Science in Public Health (Epidemiology) 2007-2009
The University of North Carolina at Chapel Hill, Chapel Hill, NC

Bachelor of Arts (Quantitative Economics and International Relations) 1999-2003
Tufts University, Medford, MA
Summa cum laude

PROFESSIONAL EXPERIENCE

Associate Professor, Department of Epidemiology Fall 2019-
Chapel Hill, NC

Director, Data Strategy and Education Fall 2019-
UNC Lineberger, Cancer Information and Public Health Resource
Chapel Hill, NC

Assistant Professor, Department of Epidemiology Fall 2013-2019
Chapel Hill, NC

Visiting Scientist, Department of Clinical Epidemiology Fall 2013-2016
Aarhus University, Aarhus, Denmark

Post-Doctoral Researcher, Department of Clinical Epidemiology 2012-2013

Aarhus University, Aarhus, Denmark

Consultant, New England Research Institute, Watertown, MA	2012-2013
Consultant, GlaxoSmithKline, Worldwide Epidemiology Research Triangle Park, NC	2012-2013
Graduate Research Assistant, GlaxoSmithKline, Worldwide Epidemiology Research Triangle Park, NC	2011-2012
Pre-doctoral Trainee, Digestive Disease Training Grant, School of Medicine Division of Gastroenterology and Hepatology The University of North Carolina at Chapel Hill	Fall 2008-2011
Graduate Research Assistant, GlaxoSmithKline, Worldwide Epidemiology Research Triangle Park, NC	Fall 2009
Graduate Research Assistant, School of Medicine, Division of Gastroenterology and Hepatology, Centro de Investigación de Demografía y Salud Leon, Nicaragua	Summer 2009
Graduate Research Assistant, School of Public Health Department of Health Policy and Management The University of North Carolina at Chapel Hill, NC	Fall 2008-2009
CRTA Fellow, National Cancer Institute, Applied Research Program Health Services and Economics Branch, Rockville, MD	Summer 2008
Graduate Research Assistant, School of Public Health Department of Health Policy and Management The University of North Carolina at Chapel Hill, NC	Spring 2008
Graduate Research Assistant, School of Public Health Department of Epidemiology The University of North Carolina at Chapel Hill, NC	Fall 2007
Senior Consultant, International Transfer Pricing Economics Ernst & Young LLP, New York, NY	2005-2007
Associate Analyst, National Economic Research Associates Healthcare Antitrust Practice, White Plains, NY	2003-2004

HONORS

International Society for Pharmacoepidemiology, Fellow Designation	April 2021
--	------------

International Society for Geriatric Oncology, Young Investigator Award, Finalist Geneva, Switzerland	Nov 2019
Society for Epidemiologic Research Poster Award Third Best Poster (Top rating among >1500 posters) Baltimore, MD	June 2018
American Society for Preventive Oncology Annual Meeting Poster Contest Honorable Mention (Top four rating among >150 posters) New York, NY	March 2018
<i>Pharmacoepidemiology and Drug Safety</i> , Outstanding Reviewer	July 2017
Gordon H. DeFriese Career Development in Aging Research Award University of North Carolina at Chapel Hill, NC	December 2014
International Society for Pharmacoepidemiology Poster Walk, First Prize Comparative Effectiveness Research Special Interest Group Taipei, Taiwan	August 2014
American Society of Hematology, Abstract Achievement Award 55 th American Society of Hematology Annual Meeting New Orleans, LA	December 2013
Delta Omega Honor Society Member, Theta Chapter University of North Carolina at Chapel Hill	2012-present
Society for Epidemiologic Research, Student Dissertation Workshop Participant 3 rd Annual North American Congress of Epidemiology Montreal, Quebec, Canada	June 2011
Society for Epidemiologic Research, Student Travel Scholarship Award Recipient 3 rd Annual North American Congress of Epidemiology Montreal, Quebec, Canada	June 2011
International Society for Pharmacoepidemiology Scholarship Recipient 26 th Annual Meeting, Brighton, United Kingdom	August 2010
Methodologies in Healthcare Outcomes in Gastroenterology Trainee Scholarship Recipient, Gastroenterology Research Group (GRP) and the American Gastroenterological Association (AGA), Chicago, IL	September 2008
Audrey L. Hale Prize recipient, Tufts University, Medford, MA	May 2003

MEMBERSHIPS

Cancer and Aging Research Group (CARG) Member	2015-present
NIA R21/R33 Health Services Research Co-Chair	2021-present
NIA R21/R33 Health Services Research Core Member	2020-2021
International Society of Geriatric Oncology	2015-present
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center	2014-present
University of North Carolina at Chapel Hill, Center for Pharmacoepidemiology	2014-present
American Society of Clinical Oncology	2011-present
Society of Epidemiological Research (SER)	2009-present
International Society for Pharmacoepidemiology (ISPE)	2009-present

BIBLIOGRAPHY

BOOKS AND CHAPTERS

1. **Lund JL**, Yabroff KR. Chapter 23: Economic Burden of Cancer Survivorship in the United States. *Cancer Rehabilitation and Survivorship: A Transdisciplinary Approach* Eds. Joanne Lester and Patricia Schmitt Oncology Nursing Society 2011; 239-46
2. Tompa E, **Lund JL**, Yabroff KR. Chapter 15: Health Economics and Cancer Survivorship. *Health Services for Cancer Survivors: Practice, Policy and Research* Eds Michael Feuerstein and Patricia A Ganz. New York: Springer; 2011; 299-328

REFEREED PAPERS: IN-PRESS AND PUBLISHED (N= 6,256 CITATIONS; H-INDEX=26)

* First author is a graduate student, post-doc, or fellow for whom I was the primary mentor.

1. **Lund JL**, Duberstein PR, Loh KP, Gilmore N, Plumb S, Lei L, Keil AP, Islam JY, Hanson LC, Giguere JK, Vogel VG, Burnette BL, Mohile SG. Life expectancy in older adults with advanced cancer: Evaluation of a geriatric assessment-based prognostic model. *Journal of Geriatric Oncology* (In-Press).
2. * Shmuel S, Pate V, Pepin MJ, Bailey JC, Golightly YM, Hanson LC, Stürmer T, Naumann RB, Gnjjidic D, **Lund JL**. Effects of Anticholinergic and Sedative Medication Use on Fractures: A Self-Controlled Design Study. *Journal of the American Geriatrics Society* (In-Press).
3. Tjia J, **Lund JL**, Mack DS, Mbrah A, Yuan Y, Chen Q, Osundolire S, McDermott CL. Methodological Challenges for Epidemiologic Studies of Deprescribing at the End of Life. *Current Epidemiology Reports*. 2021(8): 116–129.

4. Herb JN, Wolff R, McDaniel P, **Lund, JL**, Holmes M, Stitzenberg KB. “Rural Representation of the Surveillance, Epidemiology, and End Results Database” *Cancer Causes and Control* (In-Press).
5. * Hsu CD, Nichols HB, **Lund JL**. Polypharmacy and medication use by cancer history in a nationally representative group of adults in the USA, 2003-2014. *J Cancer Surviv.* (E-pub ahead of print: May 25, 2021).
6. * Gaber CE, Eluri S, Cotton CC, Strassle PD, Farrell TM, **Lund JL**, Dellon ES. Epidemiologic and Economic Burden of Achalasia in the United States. *Clin Gastroenterol Hepatol.* (E-pub ahead of print: February 27, 2021).
7. * Gaber CE, Kinlaw AC, Edwards JK, **Lund JL**, Stürmer T, Hinton SP, Pate V, Bartelt LA, Sandler RS, Peery AF. Comparative Effectiveness and Harms of Antibiotics for Outpatient Diverticulitis: Two Nationwide Cohort Studies. *Ann Intern Med.* (E-pub ahead of print: Feb 23, 2021).
8. Stürmer T, Webster-Clark M, **Lund JL**, Wyss R, Ellis AR, Lunt M, Rothman KJ, Glynn RJ. Propensity Score Weighting and Trimming Strategies to Reduce Variance and Bias of Treatment Effect Estimates: a Simulation Study. *American Journal of Epidemiology* (E-pub ahead of print: February 22, 2021).
9. * Webster-Clark MA, Keil AP, Sanoff HK, Sturmer T, Westreich D, **Lund JL**. Introducing Longitudinal Cumulative Dose to Describe Chemotherapy Patterns Over Time: Case Study of a Colon Cancer Trial. *International Journal of Cancer.* 2021 Jul 15;149(2):394-402.
10. Jackson BE, Greenup RA, Strassle PD, Deal AM, Baggett CD, **Lund JL**, Reeder-Hayes KE. Understanding and identifying immortal-time bias in surgical health services research: An example using surgical resection of stage IV breast cancer. *Surg Oncol.* 2021 Mar 5;37:101539.
11. Gartner DR, Delamater PL, Hummer RA, **Lund JL**, Pence BW, Robinson WR. Patterns of black and white hysterectomy incidence among reproductive aged women. *Health Serv Res.* 2021 Feb 21.
12. Reeder-Hayes KE, Mayer SE, **Lund JL**. Adherence to Endocrine Therapy Including Ovarian Suppression: A Large Observational Cohort Study of US Women with Early Breast Cancer. *Cancer.* 2021 Apr 15;127(8):1220-1227.
13. Moon AM, Sanoff HK, Chang Y, **Lund JL**, Barritt AS, Hayashi PH, Stitzenberg KB. Medicare/Medicaid Insurance, Rurality, and Black Race Associated With Provision of Hepatocellular Carcinoma Treatment and Survival. *J Natl Compr Canc Netw.* 2021 Feb 12:1-9.
14. Tan HJ, Zhou X, Spratte BN, McMahon S, Nielsen ME, **Lund JL**, Harris AHS, Smith AB, Basch E. Patient-Reported vs. Claims-Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer. *J Urol.* 2021 Feb;205(2):434-440.
15. * Matthews AA, Peacock Hinton S, Stanway S, Lyon AR, Smeeth L, Bhaskaran K, **Lund JL** (co-senior authors). Risk of Cardiovascular Diseases Among Older Breast Cancer Survivors in the

United States: A Matched Cohort Study. *J Natl Compr Canc Netw* (E-pub ahead of print: January 5, 2021).

16. * Matthews AA, Hinton SP, Stanway S, Lyon AR, Smeeth L, **Lund JL**, Bhaskaran K (co-senior authors). Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. *Heart* (E-pub ahead of print: November 11, 2020).
17. **Lund JL**, Webster-Clark MA, Hinton SP, Shmuel S, Stürmer T, Sanoff HK. Effectiveness of adjuvant FOLFOX vs 5FU/LV in adults over age 65 with stage II and III colon cancer using a novel hybrid approach. *Pharmacoepidemiol Drug Saf.* 2020 Dec;29(12):1579-1587.
18. * Shmuel S, Pate V, Pepin MJ, Bailey JC, Hanson LC, Stürmer T, Naumann RB, Golightly YM, Gnjjidic D, **Lund JL**. Quantifying Cumulative Anticholinergic and Sedative Drug Load Among US Medicare Beneficiaries. *Pharmacoepidemiol Drug Saf.* 2021 Feb;30(2):144-156.
19. Suarez EA, Boggess K, Engel SM, Stürmer T, **Lund JL**, Funk MJ. Ondansetron use in early pregnancy and the risk of late pregnancy outcomes. *Pharmacoepidemiol Drug Saf.* 2021 Feb;30(2):114-125.
20. Suarez EA, Boggess K, Engel SM, Stürmer T, **Lund JL**, Jonsson Funk M. Ondansetron use in early pregnancy and the risk of miscarriage. *Pharmacoepidemiol Drug Saf.* 2021 Feb;30(2):103-113.
21. * Webster-Clark M, Ross RK, **Lund JL**. Initiator Types and the Causal Question of the Prevalent New User Design. *American Journal of Epidemiology* (E-pub ahead of print: December 22, 2020).
22. Billock RM, Mucha PJ, Samoff E, Dennis AM, Pence BW, **Lund JL**, Powers KA. Network Interconnectivity and Community Detection in the HIV/Syphilis Syndemic among Men who have Sex with Men. *Sexually Transmitted Diseases.* 2020 Nov;47(11):726-732.
23. * Ross RK, Kuo TM, Webster-Clark M, Lewis CL, Kistler CE, Jonsson Funk M, **Lund JL**. Validation of a 5-Year Mortality Prediction Model among U.S. Medicare Beneficiaries. *J Am Geriatr Soc.* 2020 Dec;68(12):2898-2902.
24. * Webster-Clark M, **Lund JL**, Stürmer T, Poole C, Simpson RJ, Edwards JK. Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation. *Epidemiology.* 2020 Sep;31(5):605-613.
25. Engeda JC, Lhachimi SK, Rosamond WD, **Lund JL**, Keyserling TC, Safford MM, Colantonio LD, Muntner P, Avery CL. Projections of incident atherosclerotic cardiovascular disease and incident type 2 diabetes across evolving statin treatment guidelines and recommendations: A modelling study. *PLoS Med.* 2020 Aug 26;17(8):e1003280.
26. Spees LP, Wheeler SB, Zhou X, Amin KB, Baggett CD, **Lund JL**, Urick BY, Farley JF, Reeder-Hayes KE, Trogdon JG. Changes in chronic medication adherence, costs, and health care use after a cancer diagnosis among low-income patients and the role of patient-centered medical homes. *Cancer.* 2020 Nov 1;126(21):4770-4779.

27. * Webster-Clark M, Stürmer T, Edwards JK, Poole C, Simpson RJ Jr, **Lund JL**. Real-world on-treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults. *Pharmacoepidemiol Drug Saf*. 2020 Aug;29(8):832-841.
28. Corty RW, Langworthy BW, Fine JP, Buse JB, Sanoff HK, **Lund JL**. Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer. *Oncologist*. 2020 Jul;25(7):579-584.
29. * Chun DS, Faso A, Muss HB, Sanoff HK, Valgus J, **Lund JL**. Oncology pharmacist-led medication reconciliation among cancer patients initiating chemotherapy. *J Oncol Pharm Pract*. 2020 Jul;26(5):1156-1163.
30. **Lund JL**, Gupta P, Amin KB, Meng K, Urick BY, Reeder-Hayes KE, Farley JF, Wheeler SB, Spees L, Trogdon JG. Changes in chronic medication adherence in older adults with cancer versus matched cancer-free cohorts. *J Geriatr Oncol*. 2021 Jan;12(1):72-79.
31. Gartner DR, Delamater PL, Hummer RA, **Lund JL**, Pence BW, Robinson WR. Integrating Surveillance Data to Estimate Race/Ethnicity-specific Hysterectomy Inequalities Among Reproductive-aged Women: Who's at Risk? *Epidemiology*. 2020 May;31(3):385-392.
32. Cole AL, Wood WA Jr, Muluneh B, **Lund JL**, Elston Lafata J, Dusetzina SB. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib. *JCO Oncol Pract*. 2020 May;16(5):e443-e455.
33. BrintzenhofeSzoc K, Krok-Schoen JL, Canin B, Parker I, MacKenzie AR, Koll T, Vankina R, Hsu CD, Jang B, Pan K, **Lund JL**, Starbuck E, Shahrokni A. The underreporting of phase III chemotherapeutic clinical trial data of older patients with cancer: A systematic review. *J Geriatr Oncol*. 2020 Apr;11(3):369-379.
34. Wong ML, Lichtman SM, Morrow GR, Simmons J, Hargraves T, Gross CP, **Lund JL**, Lowenstein LM, Walter LC, McDermott CL, Mohile SG, Cohen HJ. Geriatric oncology health services research: Cancer and Aging Research Group Infrastructure Core. *J Geriatr Oncol*. 2020 Mar;11(2):350-354.
35. Kirkegård J, Gaber C, **Lund JL**, Hinton SP, Ladekarl M, Heide-Jørgensen U, Cronin-Fenton D, Mortensen FV. Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis. *Cancer Epidemiol*. 2020 Feb;64:101647.
36. * Hsu CD, Hinton SP, Reeder-Hayes KE, Sanoff HK, **Lund JL**. Association between Concomitant Use of Hydrochlorothiazide and Adverse Chemotherapy-Related Events among Older Women with Breast Cancer Treated with Cyclophosphamide. *Cancer Epidemiol Biomarkers Prev*. 2020 Feb;29(2):520-523.
37. * Kirkegård J, **Lund JL**, Mortensen FV, Cronin-Fenton D. Statins and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis: A Danish nationwide population-based cohort study. *International Journal of Cancer*. 2020 Feb 1;146(3):610-616.

38. * Mitchell AP, Kinlaw AC, Peacock-Hinton S, Dusetzina SB, Sanoff HK, **Lund JL**. Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. *Oncologist*. 2020 Jan;25(1):46-54.
39. Rivera DR, Gokhale MN, Reynolds MW, Andrews EB, Chun D, Haynes K, Jonsson-Funk ML, Lynch KE, **Lund JL**, Strongman H, Bhullar H, Raman SR. Linking electronic health data in pharmacoepidemiology: Appropriateness and feasibility. *Pharmacoepidemiol Drug Saf*. 2020 Jan;29(1):18-29.
40. Pratt NL, Mack CD, Meyer AM, Davis KJ, Hammill BG, Hampp C, Setoguchi S, Raman SR, Chun DS, Stürmer T, **Lund JL**. Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. *Pharmacoepidemiol Drug Saf*. 2020 Jan;29(1):9-17.
41. Stürmer T, Wang T, Golightly YM, Keil A, **Lund JL**, Jonsson Funk M. Methodological considerations when analysing and interpreting real-world data. *Rheumatology (Oxford)*. 2020 Jan 1;59(1):14-25.
42. Strassle PD, Sickbert-Bennett EE, Klompas M, **Lund JL**, Stewart PW, Marx AH, DiBiase LM, Weber DJ. Incidence and risk factors of non-device-associated pneumonia in an acute-care hospital. *Infect Control Hosp Epidemiol*. 2020 Jan;41(1):73-79.
43. * Shmuel S, **Lund JL**, Alvarez C, Hsu CD, Palta P, Kucharska-Newton A, Jordan JM, Nelson AE, Golightly YM. Polypharmacy and Incident Frailty in a Longitudinal Community-based Cohort Study. *Journal of the American Geriatrics Society* 2019 Dec;67(12):2482-2489.
44. * Htoo P, Stürmer T, Funk MJ, Pate V, Simpson RJ, **Lund JL**. Renin-Angiotensin-Aldosterone System-Based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries. *Epidemiology*. 2019 Nov;30(6):867-875.
45. Strassle PD, Sickbert-Bennett EE, Klompas M, **Lund JL**, Stewart PW, Marx AH, DiBiase LM, Weber DJ. Incidence and risk factors of non-device-associated urinary tract infections in an acute-care hospital. *Infect Control Hosp Epidemiol*. 2019 Nov;40(11):1242-1247.
46. Anderson C, **Lund JL**, Weaver MA, Wood WA, Olshan AF, Nichols HB. Disparities in mortality from noncancer causes among adolescents and young adults with cancer. *Cancer Epidemiology, Biomarkers, and Prevention*. 2019 Sep;28(9):1417-1426.
47. Kehoe LA, Xu H, Duberstein P, Loh KP, Culakova E, Canin B, Hurria A, Dale W, Wells M, Gilmore N, Kleckner AS, **Lund JL**, Kamen C, Flannery M, Hoerger M, Hopkins JO, Liu JJ, Greer J, Epstein R, Mohile SG. Quality of Life of Caregivers of Frail Older Patients with Advanced Cancer. *The Journal of the American Geriatrics Society* (In-Press).
48. Garry EM, Buse JB, Gokhale M, **Lund JL**, Nielson ME, Pate V, Stürmer T. Study Design Choices for Evaluating Comparative Safety of Diabetic Medications: An Evaluation of Pioglitazone and Bladder Cancer Risk Among Older US Adults with Type-2 Diabetes. *Diabetes, Obesity, and Metabolism*. 2019 Sep;21(9):2096-2106.

49. * Yang JY, Webster-Clark M, **Lund JL**, Sandler RS, Dellon ES, Stürmer T. Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research. *Gastrointestinal Endoscopy*. 2019 Sep;90(3):360-369.
50. Zhang HT, McGrath LJ, Ellis AR, Wyss R, **Lund JL**, Stürmer T. Restriction of Pharmacoepidemiologic Cohorts to Initiators of Unrelated Preventive Drug Classes to Reduce Confounding by Frailty in Older Adults. *American Journal of Epidemiology*. 2019 Jul 1;188(7):1371-1382.
51. Loh KP, Mohile SG, **Lund JL**, Epstein R, MD, Lei L. Culakova E, McHugh C, Wells M, Gilmore N, Mohamed MR, Kamen C, Aarne V Conlin A, Bearden J, Onitilo A, Wittink M, Dale W, Hurria A, Duberstein P. Beliefs about advanced cancer curability in older patients, their caregivers, and oncologists. *The Oncologist*. 2019 Jun;24(6):e292-e302.
52. Lycke KD, Christiansen CF, **Lund JL**, Iversen LH, Nørgaard M. Preadmission use of antidepressants and risk of complications and death after colorectal cancer surgery: A nationwide population-based cohort study. *Colorectal Diseases* 2019 Jun;21(6):651-662.
53. Anderson C, **Lund JL**, Weaver MA, Wood WA, Olshan AF, Nichols HB. Noncancer mortality among adolescents and young adults with cancer. *Cancer* 2019 Jun 15;125(12):2107-2114.
54. **Lund JL**, Kuo M, Brookhart MA, Meyer AM, Dalton AF, Kistler CE, Wheeler SB, Lewis CL. Development and validation of a five-year mortality prediction model using machine learning and Medicare data. *Pharmacoepidemiology and Drug Safety* 2019 May;28(5):584-592.
55. Mitchell AP, Winn AN, **Lund JL**, Dusetzina SB. Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology. *The Oncologist* 2019 May;24(5):632-639.
56. Williams GR, Dunham L, Chang YK, Deal AM, Pergolotti M, **Lund JL**, Guerard E, Kenzik K, Muss HB, and Sanoff HK. Geriatric Assessment Predicts Hospitalization Frequency and Long-Term Care Utilization in Older Adult Cancer Survivors. *Journal of Oncology Practice* 2019 May;15(5):e399-e409.
57. Engeda JC, Stackhouse A, White M, Rosamond WD, Lhachimi SK, **Lund JL**, Keyserling TC, Avery CL. Evidence of heterogeneity in statin-associated type 2 diabetes mellitus risk: A meta-analysis of randomized controlled trials and observational studies. *Diabetes Research and Clinical Practice* 2019 May;151:96-105.
58. * Yang JY, Peery AF, **Lund JL**, Pate V, Sandler RS. Burden and Cost of Outpatient Hemorrhoids in the United States Employer-Insured Population, 2014. *American Journal of Gastroenterology* 2019 May;114(5):798-803.
59. * Hester LL, Park SI, Wood WA, Stürmer T, Brookhart MA, **Lund JL**. Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes in the rituximab era. *Cancer* 2019 Apr 1;125(7):1101-1112.

60. * Mayer SE, Tan HJ, Hinton SP, Sanoff HK, Stürmer T, Hester LL, Faurot KR, Funk MJ, **Lund JL**. Comparison of Medicare claims-based measures of poor physical function and associations with treatment receipt and mortality in older colon cancer patients. *Medical Care* 2019 Apr;57(4):286-294.
61. Van Rompay MI, Nickel JC, Ranganathan G, Kantoff PW, Solomon KR, **Lund JL**, McKinlay JB. Impact of 5 α -Reductase Inhibitors and α -Blockers for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality. *British Journal of Urology International* 2019 Mar;123(3):511-518.
62. Nishijima TF, Deal AM, **Lund JL**, Nyrop KA, Muss HB, Sanoff HK. Inflammatory markers and overall survival in older adults with cancer. *Journal of Geriatric Oncology* 2019 Mar;10(2):279-284.
63. * Chun D, **Lund JL**, Til Stürmer. Pharmacoepidemiology and Drug Safety's special issue on validation studies. *Pharmacoepidemiology and Drug Safety* 2019 Feb;28(2):123-125.
64. AF Peery, Crockett SD, Murphy CC, **Lund JL**, Dellon ED, Williams JL, Jensen ET, NJ Shaheen, Barritt AS, Lieber SR, Kochar B, Barnes EL, Fan YC, Baron TH, Galanko J, Sandler RS. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. *Gastroenterology* 2019 Jan;156(1):254-272.
65. Barry EL, **Lund JL**, Westreich D, Mott LA, Ahnen DJ, Beck GJ, Bostick RM, Bresalier RS, Burke CA, Church TR, Rees JR, Robertson DJ, Baron JA. Body Mass Index, Calcium Supplementation and Risk of Colorectal Adenomas. *International Journal of Cancer* 2019 Feb 1;144(3):448-458.
66. * Webster-Clark MA, Sanoff HK, Stürmer T, Hinton SP, **Lund JL**. Diagnostic assessment of transportability of intervention effects from a randomized trial to a routine care population: An application to metastatic colorectal cancer. *Epidemiology* 2019 Jan;30(1):103-111.
67. Young JC, **Lund JL**, Dasgupta N, Jonsson Funk M. Opioid tolerance and clinically recognized opioid poisoning among patients prescribed extended-release long-acting opioids. *Pharmacoepidemiology and Drug Safety* 2019 Jan;28(1):39-47.
68. Naumann RB, Marshall SW, Gottfredson NC, **Lund JL**, Ringwalt CL, Skinner AC. Trajectories of dispensed prescription opioids among beneficiaries enrolled in a Medicaid controlled substance "lock-in" program. *Pharmacoepidemiology and Drug Safety* 2019 Jan;28(1):16-24.
69. * D'Arcy M, Stürmer T, **Lund JL**. The importance and implications of comparator selection in pharmacoepidemiologic research. *Current Epidemiology Reports* 2018 Sep;5(3):272-283.
70. Yuan H, Ali MS, Brouwer ES, Girman CJ, Guo JJ, **Lund JL**, Paterno E, Slaughter JL, Wen X, Bennett D; ISPE Comparative Effectiveness Research Special Interest Group. Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG). *Clinical Pharmacology and Therapeutics* 2018 Aug;104(2):239-241.

71. * Cuthbertson CC, Kucharska-Newton A, Stürmer T, Faurot KR, Bandeen-Roche KL, Funk MJ, Palta P, **Lund JL**. Validating a Medicare Claims-Based Model to Classify Phenotypic Frailty in Older Adults. *Epidemiology* 2018 Jul;29(4):556-561.
72. Nishijima TF, Deal AM, **Lund JL**, Nyrop KA, Muss HB, Sanoff HK. The incremental value of a geriatric assessment-derived three-item scale on estimating overall survival in older adults with cancer. *Journal of Geriatric Oncology* 2018 Jul;9(4):329-336.
73. Smitherman AB, Anderson C, **Lund JL**, Bensen JT, Rosenstein DL, Nichols HB. Frailty and Comorbidities Among Survivors of Adolescent and Young Adult Cancer: A Cross-Sectional Examination of a Hospital-Based Survivorship Cohort. *Journal of Adolescent and Young Adult Oncology* 2018 Jun;7(3):374-383.
74. Kalbaugh CA, Loehr L, Wruck L, **Lund JL**, Matsushita K, Bengtson LGS, Heiss G, Kucharska-Newton A. Inpatient or Outpatient Setting: The ARIC (Atherosclerosis Risk in Communities) Study. *Journal of the American Heart Association* 2018 Apr 13;7(8).
75. Williams GR, Deal AM, **Lund JL**, Chang YK, Muss HB, Pergolotti M, Guerard EJ, Shachar SS, Wang Y, Kenzik K, Sanoff HK. Patient-Reported Comorbidity and Survival in Older Adults with Cancer. *The Oncologist* 2018 Apr;23(4):433-439.
76. Herzog MM, Marshall SW, **Lund JL**, Pate V, Mack CD, Spang JT. Trends in Incidence of ACL Reconstruction and Concomitant Procedures Among Commercially Insured Individuals in the United States, 2002-2014. *Sports Health*. 2018 Nov/Dec; 10(6): 523-53.
77. Naumann RB, Marshall SW, **Lund JL**, Gottfredson NC, Ringwalt CL, Skinner AC. Evaluating short- and long-term impacts of a Medicaid "lock-in" program on opioid and benzodiazepine prescriptions dispensed to beneficiaries. *Drug and Alcohol Dependence*. 2018 Jan 1;182:112-119.
78. * Landi SN, Sandler RS, Pate V, **Lund JL**. No Increase in Acute Myocardial Infarction Risk in Proton Pump Inhibitor vs Histamine-2 Receptor Antagonist Users. *Gastroenterology* 2018 Mar;154(4):861-873.
79. Mohiuddin JJ, Deal AM, **Lund JL**, Carey LA, Baker BR, Zagar TM, Jones EL, Marks LB, Chen RC. Evaluating the Effectiveness of Neoadjuvant Chemotherapy in Reducing Mastectomy for Women With Breast Cancer. *JNCI Cancer Spectrum* (E-pub ahead of print: September 27, 2017).
80. * Østgård LS, **Lund JL**, Nørgaard JM, Nørgaard M, Medeiros BC, Nielsen B, Nielsen OJ, Overgaard UM, Kallenbach M, Marcher CW, Riis AH, Sengeløv H. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: a National population-based Cohort Study. *Biology of Blood and Marrow Transplantation*. 2018 Feb;24(2):314-323.
81. **Lund JL**, Sanoff HK, Hinton SP, Muss HB, Pate V, Stürmer T. Potential Medication-Related Problems in Older Breast, Colon, and Lung Cancer Patients in the United States. *Cancer Epidemiol Biomarkers Prev*. 2018 Jan;27(1):41-49.

82. Chollet-Hinton L, Olshan AF, Nichols HB, Anders CK, **Lund JL**, Allott EH, Bethea TN, Hong CC, Cohen SM, Khoury T, Zirpoli GR, Borges VF, Rosenberg LA, Bandera EV, Ambrosone CB, Palmer JR, Troester MA. Biology and etiology of young-onset breast cancers among premenopausal African American women: results from the AMBER Consortium. *Cancer Epidemiol Biomarkers Prev.* 2017 Dec;26(12):1722-1729.
83. **Lund JL**, Puhó EH, Szépligeti SK, Sorensen HT, Pedersen L, Ehrenstein V, Stürmer T. Conditioning on Future Exposure to Define Study Cohorts Can Induce Bias: The case of low-dose acetylsalicylic acid and risk of major bleeding. *Clinical Epidemiology.* 2017 Nov 23;9:611-626
84. Kinlaw AC, Stürmer T, **Lund JL**, Pedersen L, Daniels JL, Kappelman MD, Sørensen HT. Birth cohort effects on antibiotic prescribing during infancy. *Pediatrics.* 2017 Sep;140(3).
85. Garry EM, Buse JB, **Lund JL**, Pate V, Stürmer T. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. *Diabetes Obesity and Metabolism.* 2017 Dec;26(12):1722-1729.
86. Mariano C, **Lund JL**, Hinton SP, Htoo P, Muss HB, Reeder-Hayes KR. Measuring the Association Between Adjuvant Chemotherapy and Function-Related Adverse Events among Older Breast Cancer Patients. *Journal of Geriatric Oncology.* 2017 Jul;8(4):242-248.
87. DeBono N, Robinson WR, **Lund JL**, Tse CK, Moorman PG, Olshan AF, Troester MA. Race, menopausal hormone therapy, and invasive breast cancer in the Carolina Breast Cancer Study. *Journal of Women 's Health* 2018 Mar;27(3):377-386.
88. * Guerard EJ, Deal AM, Chang YK, Williams GR, Nyrop KA, Pergolotti M, Muss HB, Sanoff HK, **Lund JL**. Frailty Index Developed from a Cancer-Specific Geriatric Assessment and the Association with Mortality among Older Adults with Cancer. *Journal of the National Comprehensive Cancer Network.* 2017 Jul;15(7):894-902.
89. Murphy CC, **Lund JL**, Sandler RS. Young-onset colorectal cancer: earlier diagnoses or increasing disease burden? *Gastroenterology.* 2017 Jun;152(8):1809-1812.
90. Herzog MH, Marshall SW, **Lund JL**, Pate V, Mack CD, Spang JT. Increasing Incidence of ACL Reconstruction Among Adolescent Females in the United States, 2002-2014. *JAMA Pediatrics.* 2017 Aug 1;171(8):808-810.
91. Kalbaugh CA, Kucharska-Newton A, Wruck L, **Lund JL**, Selvin E, Matsushita K, Bengtson LS, Heiss G, Loehr L. Peripheral artery disease prevalence and incidence estimated from both outpatient and inpatient settings among Medicare fee-for-service beneficiaries in the Atherosclerosis Risk in Communities (ARIC) study. *Journal of the American Heart Association* 2017: 3;6(5).
92. **Lund JL**, Meyer AM, Deal AM, Choi BJ, Chang YK, Williams GR, Pergolotti M, Guerard EJ, Muss HB, Sanoff HK. Data Linkage to Improve Geriatric Oncology Research: A Feasibility Study. *The Oncologist.* 2017 Aug;22(8):1002-1005.

93. Hong JL, Henderson LM, Funk MJ, **Lund JL**, Buse J, Pate V, Sturmer T. Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea. *Pharmacoepidemiology and Drug Safety*. 2017 Jun;26(6):666-675.
94. Gokhale M, Buse JB, Jonsson Funk M, **Lund J**, Pate V, Simpson RJ, Sturmer T. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives. *Diabetes, Obesity, and Metabolism*. 2017 Jul;19(7):970-978.
95. Erichsen R, Horvath-Puho E, **Lund JL**, Dellon ES, Shaheen NJ, Pedersen L, Smith GD, Sørensen HT. Mortality and cardiovascular diseases risk in patients with Barrett's oesophagus: a population-based nationwide cohort study. *Alimentary Pharmacology and Therapeutics*. 2017 Apr;45(7):973-982.
96. Murphy CC, Sanoff HK, Stitzenberg KB, Baron JA, **Lund JL**, Sandler RS. Patterns of Sociodemographic and Clinicopathologic Characteristics of Stages II and III Colorectal Cancer Patients by Age: Examining Potential Mechanisms of Young-Onset Disease. *Journal of Cancer Epidemiology* 2017;2017:4024580.
97. Murphy CC, Sandler RS, Sanoff HK, Yang YC, **Lund JL**, Baron JA. Decrease in incidence of colorectal cancer among individuals 50 years or older following recommendations for population-based screening. *Clinical Gastroenterology and Hepatology*. 2017 Jun;15(6):903-909.
98. Kucharska-Newton A, Palta P, Burgard S, Griswold M, **Lund JL**, Capistrant B, Kritchevsky S, Bandeen-Roche K, Windham BG. Operationalizing frailty in the Atherosclerosis Risk in Communities (ARIC) Study cohort. *Journal of Gerontology: Medical Sciences*. 2017 72(3):382-388.
99. Sanoff HK, Chang YK, Reimers M, **Lund JL**. Hospice Utilization and Its Effect on Acute Care Needs at the End of Life in Medicare Beneficiaries with Hepatocellular Carcinoma. *Journal of Oncology Practice*. 2017 13(3):e197-e206.
100. Hong JL, Funk MJ, Buse J, Henderson LM, **Lund JL**, Pate V, Stürmer T. Comparative effect of Initiating Metformin versus Sulfonylureas on Breast Cancer Risk in Older Women. *Epidemiology*. 2017 28(3):446-454.
101. Herzog MH, Marshall SW, Pate V, **Lund JL**, Spang JT. Cost of Outpatient Arthroscopic Anterior Cruciate Ligament Reconstruction Among Commercially Insured Patients in the United States, 2005-2013. *The Orthopaedic Journal of Sports Medicine*. 2017; 5(1): 1-8.
102. Mohiuddin JJ, Deal AM, Carey LA, **Lund JL**, Baker BR, Zagar TM, Jones EL, Marks LB, Chen RC. Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States. *Journal of the American College of Surgeons*. 2016; 223(5):717-728.
103. Noone AM, **Lund JL**, Mariotto A, Cronin K, Deapen D, Warren JL. Comparison of SEER Treatment Data with Medicare Claims. *Medical Care* 2016; 54(9):e55-64.

104. Sanoff HK, Chang YK, **Lund JL**, O'Neil BH, Dusetzina SB. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. *The Oncologist*. 2016; 21(9):1113-20.
105. Jiron M, Pate V, Hanson LC, **Lund JL**, Jonsson Funk M, Stürmer T. Trends in prevalence and determinants of potentially inappropriate prescribing in the US 2007-2012. *Journal of the American Geriatrics Society*. 2016; 64(4): 788-97.
106. Young JC, Sturmer T, **Lund JL**, Jonsson Funk M. Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data. *Pharmacoepidemiology and Drug Safety*. 2016; 25(7): 836-43.
107. Søgaard KK, Farkas DK, Pedersen L, **Lund JL**, Thomsen RW, Sørensen HT. Long-term Risk of Gastrointestinal Cancers in Persons with Gastric or Duodenal Ulcers. *Cancer Medicine* 2016; 5(6):1341-51.
108. **Lund JL**, Sturmer T, Sanoff HK. Comparative effectiveness of postoperative chemotherapy among older non-metastatic rectal cancer patients treated with preoperative chemoradiotherapy. *Journal of Geriatric Oncology* 2016; 7(3):176-86.
109. **Lund JL**, Richardson DB, Sturmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. *Current Epidemiology Reports*. 2015; 2(4): 221-28.
110. **Lund JL**, Østgård LS, Prandoni P, Sorensen HT, Brown PD. Incidence, Determinants and the Transient Impact of Cancer Treatments on Venous Thromboembolism Risk among Lymphoma Patients in Denmark. *Thrombosis Research* 2015; 136(5): 917-23.
111. Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, Jensen ET, **Lund JL**, Pasricha S, Runge T, Schmidt M, Shaheen NJ, Sandler RS. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. *Gastroenterology* 2015;149(7): 1731-41
112. Sanoff HK, Chang YK, Stavas JM, Stürmer T, **Lund JL**. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries. *Journal of the National Comprehensive Cancer Network* 2015; 13(9): 1102-10
113. Murphy CC, Harlan LC, **Lund JL**, Lynch CF, Geiger AM. Patterns of colorectal cancer care in the United States: 1990-2010. *Journal of the National Cancer Institute* 2015; 107(10): 1-11.
114. Sanoff HK, Morris WL, Micheltree AL, Wilson S, **Lund JL**. Lack of Support and Information Regarding Long-Term Negative Effects in Survivors of Rectal Cancer. *Clinical Journal of Oncology Nursing* 2015; 19(4): 444-48.
115. Hall SA, Ranganathan G, Tinsley LJ, **Lund JL**, Kupelian V, Wittert GA, Kantoff PW, Morales A, Araujo AB. Population-based patterns of prescription androgen use in Saskatchewan, Canada, 1976-2008. *Pharmacoepidemiology and Drug Safety* 2014; 23(5): 498-506.
116. Søgaard KK, Erichsen R, **Lund JL**, Farkas DK, Sørensen HT. Cholangitis and Subsequent Gastrointestinal Cancer Risk: A Danish Population-Based Cohort Study. *Gut* 2014; 63(2): 356-61.

117. **Lund JL**, Cook SF, Allen JK, Carroll CF, Kappelman MD. Patterns of 6-mercaptopurine and azathioprine maintenance therapy among a cohort of commercially insured individuals diagnosed with Crohn's disease in the United States. *Clinical Epidemiology* 2013; 5:501-12.
118. **Lund JL**, Froslev T, Deleuran T, Erichsen R, Nilsson T, Pedersen AN, Hoyer M. Validity of the Danish National Registry of Patients for chemotherapy reporting among colorectal cancer patients is high. *Clinical Epidemiology* 2013; 5:327-34.
119. **Lund JL**, Stürmer T, Sanoff HK, Brookhart MA, Sandler RS, Warren JL. Determinants of Adjuvant Oxaliplatin Receipt Among Older Stage II and III Colorectal Cancer Patients. *Cancer* 2013; 119: 2038-47.
120. **Lund JL**, Stürmer T, Harlan LC, Sanoff HS, Sandler RS, Brookhart MA, Warren JL. Identifying specific chemotherapeutic agents in Medicare data: a validation study. *Medical Care* 2013; 51(5): e27-34.
121. Butler EN, Chawla N, **Lund J**, Harlan LC, Warren JL, Yabroff KR. Patterns of colorectal cancer care in the United States and Canada: a systematic review. *Journal of the National Cancer Institute Monograph* 2013; 46: 13-35.
122. Chawla N, Butler EN, **Lund J**, Warren JL, Harlan LC, Yabroff KR. Patterns of colorectal cancer care in Europe, Australia, and New Zealand. *Journal of the National Cancer Institute Monograph* 2013; 46: 36-61.
123. Dominguez RL, Crockett SD, **Lund JL**, Suazo LP, Davis PH, Martin C, Morgan DR. Gastric cancer incidence estimation in a resource-limited nation: use of endoscopy registry methodology. *Cancer Causes and Control* 2013; 24(2): 233-39.
124. Peery AF, Dellon ES, **Lund J**, Crockett SD, McGowan C, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, DiBonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ. Burden of Gastrointestinal Disease in the United States, 2012. *Gastroenterology* 2012; 143(5):1179-87.
125. Yabroff KR, **Lund JL**, Kepka D, Mariotto A. Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research. *Cancer Epidemiology, Biomarkers and Prevention*, 2011; 20(10): 2006-2014.
126. Federspiel JJ, Stearns S, van Domburg RT, Sheridan BC, **Lund JL**, Serruys PW. Risk-Benefit Trade-offs in Revascularization Choices. *EuroIntervention*. 2011; 6(8): 936-41.
127. Weiner BJ, Amick HR, **Lund JL**, Lee DS, Hoff TJ. Use of Qualitative Methods in Published Health Services and Management Research: A Ten-Year Review. *Medical Care Research and Review*. 2011; 68(1): 3-33.
128. **Lund JL**, Stürmer T, Porter C, Sandler RS, Kappelman MD. Thiazolidinedione use and ulcerative colitis related flares: an exploratory analysis of administrative data. *Inflammatory Bowel Diseases*. 2011; 17(3): 787-94.

129. **Lund JL**, Harlan LC, Yabroff KR, Warren JL. Should Cause of Death From the Death Certificate Be Used to Examine Cancer-Specific Survival? A Study of Patients with Distant Stage Disease. *Cancer Investigation*. 2010; 28(7):758-64.
130. **Lund JL**, Yabroff KR, Ibuka Y, Russell LB, Barnett PG, Lipscomb J et al. Inventory of data sources for estimating health care costs in the United States. *Medical Care*. 2009; 47: S127-S142.

LETTERS TO THE EDITOR

1. Mamtani R, **Lund J**, Hubbard RA: Considering the totality of evidence: Combining real-world data with clinical trial results to better inform decision-making. *Pharmacoepidemiology & Drug Safety* 30: 814-816, March 2021.
2. Shmuel S, Yang JY, Thai S, Webster-Clark MA, **Lund JL**. Assessing Clinical Trial Effects on Outcomes Among Pediatric and Adolescent and Young Adult (AYA) Patients With Cancer. *Cancer*. 2021; 127(4):648-649.
3. Kirkegård J, **Lund JL**, Mortensen FV, Cronin Fenton D. Reply to: "Design flaws in statins and pancreatic cancer research". *International Journal of Cancer*. 2019;145(5):1450-1451.
4. Li X, **Lund JL**, Toh S. Lower Cancer Incidence: Warfarin effect or Immortal Time Bias? *JAMA Internal Medicine* 2018; 178(4):584-5.
5. Murphy CC, Sanoff HK, Baron JA, Stitzenberg KB, Y. Yang C, Sandler RS, **Lund JL**. Re: Colorectal cancer incidence patterns in the United States, 1974—2013. *Journal of the National Cancer Institute*. 2017; 109(8): 104.
6. Sanoff HK, Chang YK, **Lund JL**, O’Neil B, Dusetzina SB. Immortal Time Bias or Sorafenib Effect in Elderly Patients with HCC? *Hepatology*. 2017; 66(2):678-679.
7. **Lund JL**, Montomoli J. Common Flaws in Pharmacoepidemiologic Study Design and Analysis *Journal of Clinical Oncology* 2013; 31(32):4161-2.
8. **Lund JL**, Stürmer T, Sørensen HT. Benefits and Risks of Aspirin Use. *JAMA* 2012; 308(11): 1088-89.

SELECTED ORAL PRESENTATIONS FROM SUBMITTED ABSTRACTS

1. Hester LL, Seeger J, Davis K, Golozar A, Sansbury L, **Lund JL**. Concurrent Workshop - Using Real-world External Controls to Support Drug Approval: An Interactive Framework Using Oncology Trial and Real-world Data. *ICPE All Access Virtual Meeting*, August 24, 2021.
2. **Lund JL**. Current Methodological Challenges and Future Directions for Frailty Measurement in Pharmacoepidemiology. Part of the symposium titled, “At the intersection of frailty and

pharmacoepidemiology: Foundations, applications, and future directions". *ICPE All Access Virtual Meeting*, December 8, 2020.

Available through *Pharmacoepidemiology and Drug Safety* 2020; 29(S3): MY01.

3. **Lund JL**, Webster-Clark MA, Keil AP, Westreich D, Stürmer T, Sanoff HK. Transporting treatment effects from clinical trials to clinical practice using a hybrid study approach: The case of adjuvant FOLFOX versus 5FU for colon cancer treatment. *ICPE All Access Virtual Meeting*, September 16-17, 2020.

Available through *Pharmacoepidemiology and Drug Safety* 2020; 29(S3): 115.

4. * Webster-Clark MA, Keil AP, Sanoff HK, Stürmer T, Westreich D, **Lund JL**. Longitudinal cumulative dose: A novel measure to evaluate multiple dimensions of chemotherapy adherence over time. *ICPE All Access Virtual Meeting* September 16-17, 2020.

Available through *Pharmacoepidemiology and Drug Safety* 2020; 29(S3): 198.

5. Garry EM, Buse JB, Gokhale M, **Lund JL**, Pate V, Stürmer T. Implementation of the prevalent new user study design in the US Medicare population: Benefit versus harm. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 167.

6. * Mayer SE, Pate V, Hanson LC, Jonsson Funk M, Faurot KR, Stürmer T, **Lund JL**. Improving claims-based frailty prediction in the Medicare population using STOPPFrail drug criteria. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 193.

7. Herzog MM, **Lund JL**, Pate V, Spang JT, Marshall SW. Association between fluoroquinolone use and anterior cruciate ligament injury in the United States. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 376.

9. Chubak JC, Newcomer S, **Lund JL**. Thinking beyond diagnosis, procedure, and drug codes: Shaping the future of epidemiologic research using electronic healthcare databases. *51st Annual Meeting of the Society for Epidemiologic Research*, Baltimore, MD, June 19-22, 2018.

10. **Lund JL**, Hinton SP, Stürmer T. Potential Pitfalls in Using the Beers Criteria to Identify Potentially Inappropriate Medications in the Context of an Index Event. *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 13.

11. Kinlaw AC, Sorensen HT, **Lund JL**, Pedersen L, Daniels JL, Kappelman MD, Mack CD, Steiner MJ, Froslev T, Stürmer T. Antibiotic Prescribing During Infancy and Risk of Treated Airway

Diseases Among Children Born in Denmark 2004–2012. *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 25.

12. * Hester LL, Brookhart MA, Stürmer T, **Lund JL**. Developing a Comorbidity Risk Prediction Model for Older Adults with Indolent Non-Hodgkin Lymphoma. *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 209.

13. * Yang JY, Sanoff HK, Sandler RS, Stürmer T, Jonsson Funk J, **Lund JL**. Does Proton-Pump Inhibitor Use Diminish Capecitabine Efficacy in Advanced Cancer Patients? *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 222.

14. * D’Arcy ME, Stürmer T, **Lund JL**. Improving Identification of Incident Colorectal (CRC) Cancer and Differentiation by Cancer Site Using Claims Data and a Multistage, Machine Learning, Classification and Regression Tree (CART) Approach. *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 445.

15. Garry EM, Buse JB, **Lund JL**, Pate V, Stürmer T. Pioglitazone and the Risk of Bladder Cancer in Older Adults with Type 2 Diabetes: A Comparison with a Clinically Meaningful Treatment Alternative. *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 474.

16. Young JC, **Lund JL**, Dasgupta N, Funk MJ. Is Prior Opioid Tolerance Associated with Safer Use of Extended-Release Opioids? *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 486.

17. * Herzog MM, Young JC, Marshall SW, Mack CD, Pate V, **Lund JL**. Oral Contraceptive Use and Anterior Cruciate Ligament Injury: An Active Comparator New User Cohort Study. *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 553.

18. Young JC, **Lund JL**, Dasgupta N, Funk MJ. “Opioid Tolerance Prior to Initiation of High- Dose Oxycodone in Commercially-Insured Adults in the US, 2010-2014” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.

Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 20.

19. * Hester LL, Park SI, **Lund JL**. “Predictors of Induction Chemoimmunotherapy Among Older US Adults with Follicular Lymphoma” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
- Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 28.
20. * D’Arcy ME, Stürmer T, Meyer AM, Funk MJ, Sandler RS, Baron J, Troester M, **Lund JL**. “Validation of Claims-Based Definitions of Incident Colorectal Cancer (CRC) in a North Carolina (NC) Medicare Population” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
- Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 29.
21. Kinlaw AC, Sørensen HT, **Lund JL**, Pedersen L, Daniels JL, Kappelman MD, Stürmer T. “Birth Cohort Effects on Overall and Subtype- Specific Antibiotic Use Among Infants Born in Denmark 2004-2012” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
- Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 32.
22. Andrews E, Stürmer T, McGrath LJ, Funk MJ, **Lund JL**, Johannes CB, Gilsean AW, Powers C. “Exploring Innovative Methods to Conduct Validation Using United States Medicare Administrative Claims Data” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
- Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 50.
23. Herzog MH, Marshall SW, Pate V, **Lund JL**, Spang JT. “Incidence and Trends in ACL Reconstruction Among Commercially-Insured Individuals in the United States, 2002-2013” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
- Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 252.
24. * Htoo PT, Mariano CJ, Hinton SP, Hayes KR, Funk MJ, Stürmer T, **Lund JL**. “Propensity Score Methods for Subgroup Analyses: Investigating Covariate Balance” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
- Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 477.
25. * Landi SN, **Lund JL**, Pate V, Sandler RS. “Association of Proton Pump Inhibitor Use and Acute Myocardial Infarction Among Privately Insured Adults, 2001-2014” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
- Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 491.
26. Gokhale MN, Buse JB, Funk MJ, **Lund JL**, Simpson R, Stürmer T. “Comparative Incidence of Cardiovascular Events in Older Adults Initiating DPP-4 Inhibitors versus Other Antidiabetic Drugs” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
- Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 510.
27. **Lund JL**, Stürmer T, Keil AP, Picciotto S, Hernan M. “Healthy Workers and Healthy Users: Comparing Approaches to Mitigate Confounding and Selection Bias in Occupational and

Pharmaco-Epidemiology” 2016 *Epidemiology Congress of the Americas*, Miami, FL June 21-24, 2016.

28. **Lund JL**, Lash TL, Stürmer T, Aquavella J, Stovring H, Maclure M, Laden F, Lo Re V, Werler M, Sacks S. Does the Increasing Specialization of Epidemiologic Societies Ensure the Best Future for Our Profession? *31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Boston, MA August 22-26, 2015.

Available through *Pharmacoepidemiology and Drug Safety* 2015; 24(S1).

29. **Lund JL**, Sanoff HK, Stürmer T. “Controlling for markers of frailty in cancer comparative effectiveness research among older adults” *31st International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Boston, MA August 22-26, 2015.

Available through *Pharmacoepidemiology and Drug Safety* 2015; 24(S1): 2.

30. **Lund JL**, Stürmer T, Horvath-Puhó E, Szepligeti S, Pedersen L, Ehrenstein V, Baron JA. “Avoiding ‘Crystal Ball’ Epidemiology: The Case of Low-Dose Aspirin and Major Bleeding” *30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Taipei, Taiwan, October 24-27, 2014.

Available through *Pharmacoepidemiology and Drug Safety* 2014; 23(S1): 174.

31. **Lund JL**, Østgård LS, Prandoni P, Sorensen HT, Brown P. “Incidence and Predictors of venous Thromboembolism Among Lymphoma Patients in Denmark: A Nationwide Population-Based Cohort Study” *American Society of Hematology 55th Annual Meeting*, New Orleans, LA, December 5-10.

Available through *Blood* 2013; 122(21): 934

32. **Lund JL**, Schmidt M, Stürmer T, Riis AH, Pedersen L, Sorensen HT. “Do Statins Reduce Short-Term Mortality among Patients Hospitalized with Perforated Peptic Ulcers?” *29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 25-28.

Available through *Pharmacoepidemiology and Drug Safety* 2013; 22(S1): 392

SELECTED POSTER PRESENTATIONS

1. **Lund JL**, Webster-Clark MA, Sturmer T, Westreich D, Sanoff HK, Keil AP. A picture is worth 1000 words: Visual tools to guide transport of trial results to real-world populations. *ICPE All Access Virtual Meeting* September 16-17, 2020.

Available through *Pharmacoepidemiology and Drug Safety* 2020; 29(S3): 374.

2. Rivera DR, Gokhale MN, Reynolds MW, Andrews EB, Chun DC, Haynes K, Jonsson-Funk ML, Lynch KE, **Lund JL**, Strongman H, Raman SR. Linking electronic health data in pharmacoepidemiology: Guidance for assessing appropriateness and feasibility. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 88.

- Cole AL, Wood WA, Muluneh B, **Lund JL**, Lafata JE, Dusetzina SB. Predictors of tyrosine kinase inhibitor treatment for chronic myeloid leukemia. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 104.

- * Webster-Clark MA, **Lund JL**, Pate V. When prescriptions fall short: Using CPT codes to augment warfarin prescriptions in claims. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 110.

- * D'Arcy M, Stürmer T, **Lund JL**. A flexible approach to evaluating the validity of commonly used claims-based cancer algorithms. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 124.

- Lund JL**, Meng K, Urick BY, Farley JF, Amin K, Wheeler SB, Reeder-Hayes KE, Trogon JG. Changes in diabetes medication adherence in older cancer patients versus matched cancer-free cohorts: A difference-indifference analysis. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 157.

- Wang T, Gower EW, **Lund JL**, Jonsson Funk M, Pate V, Buse JB, Stürmer T. Multiple imputation of clinical variables in FFS Medicare population. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 165.

- Jiron M, Pate V, Hanson LC, **Lund JL**, Jonsson Funk M, Stürmer T. Potential omissions of angiotensin inhibition treatment among older US adults after an acute myocardial infarction. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 291.

- Jiron M, Pate V, Hanson LC, **Lund JL**, Jonsson Funk M, Stürmer T. Potential omissions of oral anticoagulant among older US adults with newly diagnosed atrial fibrillation. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 292.

- * Chun DS, Hinton SP, **Lund JL**. Potentially inappropriate medication use and emergency department visits in older women diagnosed with breast cancer initiating chemotherapy. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 295.

11. * Shmuel S, **Lund JL**, Alvarez C, Hsu CD, Palta P, Kucharska-Newton AM, Nelson AE, Golightly YM. Polypharmacy and frailty in a longitudinal community-based cohort study. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 296.
12. **Lund JL**, Pate V, Jiron M, Hanson LC, Shmuel S, Webster-Clark MA, Farley JF, Stürmer T. Improving population-level PIM exposure metrics using Medicare claims data. *34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Prague Czech Republic, August 22-26, 2018.

Available through *Pharmacoepidemiology and Drug Safety* 2018; 27(S2): 297.
13. **Lund JL**, Webster-Clark MA, Sanoff HK, Keil AP, Westreich D, Brookhart MA, Stürmer T. Generalizing randomized clinical trial results to calendar-year specific cohorts of older stage II-III colon cancer patients initiating adjuvant chemotherapy. *51st Annual Meeting of the Society for Epidemiologic Research*, Baltimore, MD, June 19-22, 2018.
14. * Mitchell AP, Kinlaw AC, Hinton SP, Sanoff HK, Basch E, **Lund JL**. Cancer Patients Receive Higher-Priced Chemotherapy When Treated in Private Practice Compared to Academic Institutions. *Academy Health Annual Research Meeting*, Seattle, WA, USA, June 24-26.
15. Mitchell AP, Winn AN, **Lund JL**, Dusetzina SB. Duration of Physician-Industry Relationships and Prescribing Changes in Oncology. *2018 American Society for Clinical Oncology (ASCO) Annual Meeting*, Chicago, IL, USA, June 1-4, 2018.
16. Nishijima TF, Deal AM, **Lund JL**, Nyrop K, Muss HB, Sanoff HK. The value of inflammatory markers in predicting overall survival in older adults with cancer. *2018 American Society for Clinical Oncology (ASCO) Annual Meeting*, Chicago, IL, USA, June 1-4, 2018.
17. Williams GR, Dunham L, Chang YK, Deal AM, Pergolotti M, **Lund JL**, Guerard E, Kenzik K, Muss HB, Sanoff HK. Geriatric assessment to predict hospitalization frequency and long-term care utilization in older adult cancer survivors. *2018 American Society for Clinical Oncology (ASCO) Annual Meeting*, Chicago, IL, USA, June 1-4, 2018.
18. **Lund JL**, Hinton SP, Hsu C, Stürmer T, Reeder-Hayes KE, Sanoff HK. Association between concomitant hydrochlorothiazide use and neutropenia-related hospitalizations among older breast and colon cancer patients treated with chemotherapy. *2018 American Society for Preventive Oncology*, New York, NY, USA, March 10-12, 2018.
19. Zhang HT, McGrath LJ, Ellis AR, Wyss R, **Lund JL**, Stürmer T. Reducing Unmeasured Confounding by Frailty Through Restriction When Estimating Influenza Vaccine Effectiveness in Older Adults. *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 531.
20. Htoo P, Gokhale M, Wyss R, **Lund JL**, Pate V, Jonsson Funk M, Buse JB, Stürmer T. Performance of Confounder Summary Scores in Estimating Subgroup Effects in Comparative Effectiveness Research. *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.

Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 492.

21. Suarez EA, **Lund JL**, Doll KM, Robinson WR. Predicting Laterality of Oophorectomy in Administrative Data with Bundled CPT Codes. *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.
Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 303.
22. * Webster-Clark MA, Sanoff HK, Stürmer T, **Lund JL**. Can We Generalize? An Example of Older Adults with Metastatic Colorectal Cancer. *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.
Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 145.
23. * Benefield HC, Sanoff HK, **Lund JL**. Describing Performance Status Changes in Older Adults During Adjuvant Chemotherapy. *33rd International Conference on Pharmaco-epidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.
Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 168.
24. * Chun DS, Faso AM, **Lund JL**. Findings from a Pharmacist-Led Medication Reconciliation for Cancer Patients Initiating a New Cycle of Chemotherapy. *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.
Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 172.
25. * Mayer SE, Tan HJ, Hinton SP, Hester LL, Stürmer T, Faurot KR, Jonsson Funk M, Sanoff HK, **Lund JL**. Medicare Claims-Based Measures of Poor Physical Function and Associations with Treatment and Mortality in Older Colon Cancer Patients. *33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Montreal, Canada, August 26-30, 2017.
Available through *Pharmacoepidemiology and Drug Safety* 2017; 26(S2): 174.
26. * Cuthbertson CC, Kucharska-Newton A, Stürmer T, Faurot KR, Bandeen-Roche KL, Funk MJ, Palta P, **Lund JL**. Validating a Medicare Claims-Based Model to Classify Phenotypic Frailty in Older Adults. 21st International Association of Gerontological Societies (IAGG) World Congress of Gerontology and Geriatrics, San Francisco, CA July 23-27, 2017.
Available through *Innovation in Aging*, 2017; 1(Supp 1): 381.
27. Kinlaw AC, Sørensen HT, **Lund JL**, Mack CD, Pedersen L, Daniels JL, Kappelman MD, Stürmer T. “The Impact of Birth Season on Time to First Antibiotic Use Among Infants Born in Denmark 2004-2012” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 68.
28. Zhang HT, McGrath LJ, Ellis AR, Wyss R, **Lund JL**, Stürmer T. “Improving Short-Term Mortality Prediction Using Timing of Acute Comorbidities During Lookback” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.
Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 140.
29. **Lund JL**, Hinton SP, Sanoff HK, Pate V, Jirón M, Burkhart JI, Muss HB, Stürmer T. “Patterns and Predictors of Potentially Inappropriate Medication Use in Older Breast, Colon, and Lung

Cancer Patients in the United States” *32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Dublin, Ireland August 25-28, 2016.

Available through *Pharmacoepidemiology and Drug Safety* 2016; 25(S3): 374.

30. **Lund JL**, Murphy CC, Peacock Hinton S, Sanoff HK, Stürmer T. “Evaluating heterogeneity of adjuvant chemotherapy effectiveness among older adults diagnosed with stage III colon cancer” *2016 Epidemiology Congress of the Americas*, Miami, FL June 21-24, 2016.
31. **Lund JL**, Sanoff HK, Stürmer T. “Identifying heterogeneity of comorbid diabetes among older colon cancer patients: A latent class analysis” *15th Annual Meeting of the International Society for Geriatric Oncology*, Prague, Czech Republic November 12-14, 2015.
Available through *Journal of Geriatric Oncology* 2015; 6(S1): S74.
32. **Lund JL**, Stürmer T, Sanoff HK. “Comparative effectiveness of contemporary adjuvant chemotherapy approaches among older rectal cancer patients” *American Society Clinical Oncology Annual Meeting*, Chicago, IL, May 29-June 2, 2014.
Available through the *Journal of Clinical Oncology* 2014; 32(15): 3579
33. **Lund JL**, Stürmer T, Sanoff HK, Sandler RS, Brookhart MA, Warren JL. “Influence of Patient, Physician, and Hospital Characteristics on Oxaliplatin Receipt among Older Stage II and III Colorectal Cancer Patients in the US” *28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management* Barcelona, Spain August 23-26, 2012
Available through *Pharmacoepidemiology and Drug Safety* 2012; 21(S3): 155
34. **Lund JL**, Erichsen R, Horvath-Puho E, Pedersen L, Davey-Smith G, Sorensen HT. “Mortality and the Risk of Cardiovascular Events in Barrett’s Esophagus.” *46th Society of Epidemiologic Research Annual Meeting* Boston, MA June 18-21, 2012
Available through *American Journal of Epidemiology* 2013; 177(Suppl 11): 151-S
35. **Lund JL**, Erichsen R, Frøslev T, Stürmer T, Sørensen HT. ”Use of Hospital Discharge Data To Monitor Trends in Chemotherapy Use among Individuals Diagnosed with Stage III Colon Cancer in Denmark, 2004–2009” *28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management* Barcelona, Spain August 23-26, 2012
Available through *Pharmacoepidemiology and Drug Safety* 2012; 21(S3): 992
36. **Lund JL**, Cook SF, Allen JK, Kappelman MD. “Patterns of 6-Mercaptopurine and Azathioprine Maintenance Therapy among Commercially Insured Individuals Diagnosed with Crohn’s Disease in the US” *28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management* Barcelona, Spain August 23-26, 2012
Available through *Pharmacoepidemiology and Drug Safety* 2012; 21(S3): 993
37. **Lund JL**, Stürmer T, Brookhart MA. “Nesting matters: A comparison of methods for analyzing non-nested clusters using the SEER-Medicare database” *45th Society of Epidemiologic Research Annual Meeting* Minneapolis, MN June 27-30, 2012
Available through *American Journal of Epidemiology* 2012; 175(Suppl 11): S18
38. **Lund JL**, Stürmer T, Sanoff HK, Sandler RS, Brookhart MA, Warren JL, Harlan LC. “Patterns of On- and Off-Label Oxaliplatin Use among Stage II and III Colorectal Cancer Patients in 2005”

27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
Chicago, IL August 14-17, 2011

Available through *Pharmacoepidemiology and Drug Safety* 2011; 20(S1): 269

39. **Lund JL**, Stürmer T, Harlan LC, Sandler RS, Sanoff HK, Brookhart MA, Warren JL. "Validation of chemotherapy drugs and combinations in Medicare data" *Third Annual North American Congress of Epidemiology* Montreal, Quebec Canada June 21-24, 2011

Available through *American Journal of Epidemiology* 2011; 173(Suppl): S207

40. **Lund JL**, Stürmer T, Sandler RS, Sanoff HK, Harlan LC, Warren JL. "Validation of specific chemotherapy drugs in Medicare data" *American Society of Clinical Oncology Annual Meeting* Chicago, IL June 3-7, 2011

Available through *Journal of Clinical Oncology*, 2011; 29 (15 Suppl): 6012

41. **Lund JL**, Dusetzina S, Gaynes B, Hansen R, and Funk MJ. "Patterns and predictors of pharmacotherapy after hospitalization for major depression" *26th International Conference on Pharmacoepidemiology and Therapeutic Risk Assessment* Providence, RI August 19-22, 2010

Available through *Pharmacoepidemiology and Drug Safety* 2010; 19(S1): 105

42. Crockett S, **Lund JL**, Dominguez R, Morgan D "Use of an Endoscopy Database as a Gastrointestinal Cancer Registry Surrogate in a Resource-Limited Nation: Experience of the Western Honduras Gastric Cancer Project. 74th Annual Scientific Meeting and Postgraduate Course of the American College of Gastroenterology San Diego, CA October 23-28, 2009

Available through *American Journal of Gastroenterology* 2009, 104(Suppl 3): S51

43. **Lund JL**, Stürmer T, Porter C, Sandler RS, Kappelman MD. "Thiazolidinedione use and ulcerative colitis related flares: an analysis of administrative data" *25th International Conference on Pharmacoepidemiology and Therapeutic Risk Assessment* Providence, RI August 16-19, 2009

Available through *Pharmacoepidemiology and Drug Safety* 2009; 18(S1): 357

44. **Lund JL**, Stürmer T, Porter C, Sandler RS, Kappelman MD. "Thiazolidinedione use and ulcerative colitis related flares: a claims database analysis" *42nd Society of Epidemiologic Research Annual Meeting Anaheim, CA June 23-26, 2009*

Available through *American Journal of Epidemiology* 2009; 169(Suppl): S13

INVITED PRESENTATIONS

1. Assessing the External Validity of Trial Results: Applications in Oncology. Johns Hopkins University, Center for Drug Safety and Effectiveness Seminar. April 12, 2021.
2. Predicting life expectancy in older adults with advanced cancer. Geriatric Oncology Symposium. Virtual Meeting. November 20, 2020.
3. Who benefits and how much in the real world? Transporting treatment effects from randomized trials to real world patient populations. UNC Gastrointestinal Epidemiology Seminar. November 4, 2020.

4. Who benefits and how much in the real world? Transporting treatment effects from randomized trials to real world patient populations. UNC Center for Pharmacoepidemiology Methods Symposium. Virtual Meeting. November 2, 2020.
5. Enhancing hybrid study designs for comparative effectiveness research. Research Triangle Symposium. RTI International, Research Triangle Park, NC, May 7, 2019.
6. The role of frailty in observation studies evaluating the comparative effectiveness and safety of medical interventions in older adults. Wake Forest Clinical Translational Sciences Institute (CTSI) Methods Conference on Emerging Methods in Translational Science: Challenges and Opportunities Across the Lifespan, Winston Salem, NC, November 9, 2018.
7. Potential medication-related problems among older adults newly diagnosed with cancer. HealthPartners Institute Seminar, Minneapolis, MN, August 14, 2018.
8. Opportunities for collaboration between LSHTM and UNC: Data resources, faculty and student interests, and a pilot collaborative project. Electronic Health Records Group Research Meeting, Department of Epidemiology, London School of Hygiene and Tropical Medicine, London, England, July 18, 2017.
9. Alternative approaches for evaluating the comparative effectiveness of cancer therapies using real world data. Epidemiology Seminar Series, Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada, January 16, 2017.
10. Evaluating the comparative effectiveness of medical interventions: Contributions from pharmacoepidemiology. GlaxoSmithKline, London, England, November 16, 2016.
11. Introduction to propensity score methods. Invited presentation to the Danish Epidemiological Society via webinar, February 8, 2016.
12. Improving the measurement of patient frailty and comorbidity using administrative data. Invited presentation at the Lineberger Comprehensive Cancer Center, Cancer Outcomes Research Program Seminar, Chapel Hill, NC, November 18, 2014.
13. Improving outcomes for older cancer patients through pharmacoepidemiologic research. Invited presentation at the Lineberger Comprehensive Cancer Center Annual Scientific Retreat, Chapel Hill, NC, May 14, 2014.
14. State of the art pharmacoepidemiological study designs for post-approval risk assessment. Invited presentation at the Cardiac Safety Research Consortium, COPD Think Tank, Silver Spring, MD, USA. March 6, 2014.
15. In the Pursuit of Happiness (and Data)... Living and working as a Postdoc in Denmark. Invited lecture at the University of Kentucky, Department of Pharmacy Practice and Science, Lexington, KY, USA. January 31, 2013.

TEACHING RECORD

COURSES

Lead Instructor, “Epidemiologic Research Using Healthcare Databases” Spring 2015, 2017, 2019, 2021
 3 credit hours; 18-33 students enrolled
 Department of Epidemiology, Gillings School of Global Public Health
 University of North Carolina at Chapel Hill

- Co-Instructor, “Epidemiology Research Methods: Proposal Writing” Fall 2020
 3 credit hours; 8 students in small group
 Department of Epidemiology, Gillings School of Global Public Health
 University of North Carolina at Chapel Hill
- Lead Instructor, “Pharmacoepidemiology of Older Adults” Spring 2016
 2 credit hours; 11 students enrolled
 Department of Epidemiology, Gillings School of Global Public Health
 University of North Carolina at Chapel Hill
- Lead Instructor, “Professional Development for Epidemiology Students” Spring 2015
 1 credit hour; 12 students enrolled
 Department of Epidemiology, Gillings School of Global Public Health
 University of North Carolina at Chapel Hill
- Small Group Instructor, “Evidence Based Medicine” Fall 2011
 8 students enrolled
 Physician Assistant Program, Duke University
 Course Director: Dr. Perri Morgan
- Small Group Co-Instructor, “Clinical Epidemiology” Fall 2011
 20 students enrolled
 School of Medicine, University of North Carolina at Chapel Hill
 Course Director: Dr. Jeffrey Sonis

SHORT COURSES

- Lead Instructor, “Applying Real-World Data (RWD) for Cancer Outcomes Research: Jul-Aug 2021
 Observational Study Design and Analytic Methods”
 US Food and Drug Administration, Virtual Training
- Co-Instructor, “Intermediate Pharmacoepidemiology” 2017- 2021
 Pre-conference course, International Conference on Pharmacoepidemiology and Therapeutic Risk Management
 Montreal, Canada (August 2017), Prague, Czech Republic (August 2018), Philadelphia, USA (August 2019), Virtual Meeting (August 2020, August 2021)
 Co-Instructors: Michele Jonsson Funk, Til Stürmer, and Sudha Raman
- Co-Instructor, “Introduction to Pharmacoepidemiology” 2015, 2016, 2017
 Pre-conference course, International Conference on Pharmacoepidemiology and Therapeutic Risk Management
 Boston, MA (August 2015), Baltimore, MD (April 2016), Dublin, Ireland (August 2016), Montreal, Canada (August 2017)
 Co-Instructors: Almut Winterstein and Tobias Gerhard
- Co-Instructor, “Pharmacoepidemiology and Comparative Effectiveness Research” Summer 2016, 2018
 Aarhus University, Department of Clinical Epidemiology, Aarhus, Denmark

Co-Instructor: Dr. Til Stürmer

Co-Instructor, “Issues and Methods in Pharmacoepidemiology” Summer 2011, 2012, 2015
Aarhus University, Department of Clinical Epidemiology, Aarhus, Denmark
Co-Instructor: Dr. Til Stürmer

GUEST LECTURES

Geriatric Oncology and Pharmacoepidemiology Fall 2015, 2016, 2017
EPID 771: Cancer Epidemiology: Survivorship and Outcomes
Department of Epidemiology, University of North Carolina at Chapel Hill

Pharmacoepidemiology and Cancer Etiology Spring 2015, 2016, 2017
EPID 770: Cancer Epidemiology and Pathogenesis
Department of Epidemiology, University of North Carolina at Chapel Hill

Instrumental Variables: Theory and Application Fall 2014
Research Seminar, Department of Clinical Epidemiology
Aarhus University Hospital, Aarhus, Denmark

Methodological issues when using medication adherence as an exposure Spring 2014
(or covariate) in comparative effectiveness research
NC TraCS, University of North Carolina at Chapel Hill

Propensity Score Methods; Introduction and Application Spring 2014
Journal Club Lecture, Department of Clinical Epidemiology
Aarhus University Hospital, Aarhus, Denmark

An Introduction to Directed Acyclic Graphs: Theory and Application Winter 2013
Journal Club Lecture, Department of Clinical Epidemiology
Aarhus University Hospital, Aarhus, Denmark

Pharmacoepidemiology in Denmark Winter 2013
Special topics in Epidemiology (Course 701)
Department of Pharmaceutical Practice and Policy
University of Kentucky, Lexington, KY

Validation Studies and Research in Denmark Winter 2013
Introduction to Pharmacoepidemiology (EPID 765)
Department of Epidemiology
University of North Carolina, Chapel Hill, NC

Cancer Epidemiology Fall 2012
Cancer Module, Department of Molecular Medicine
Aarhus University, Aarhus, Denmark

Introduction to Propensity Score Methods Fall 2012
Journal Club Lecture, Department of Clinical Epidemiology

Aarhus University Hospital, Aarhus, Denmark

Recurrent Events: An Introduction to Concepts and Analysis
Journal Club Lecture, Department of Clinical Epidemiology
Aarhus University Hospital, Aarhus, Denmark

Spring 2012

GRADUATED PHD STUDENTS

1. Danielle Chun, PhD; Graduated December 2020
Dissertation title: Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma
2. Shahar Shmuel, PhD; Graduated August 2020
Dissertation title: Anticholinergic and Sedative Drug Load in Older Adults
3. Michael Webster-Clark, PhD, PharmD; Graduated: May 2019
Dissertation title: Can We Really Rely on RE-LY? Contrasting Clinical Trial Transport and Observational Analyses
4. Laura Hester, PhD, MPH; Graduated: August 2017
Dissertation title: Patterns and Prediction of Competing Causes of Mortality among Older Adults with Indolent Non-Hodgkin Lymphoma
5. Monica D'Arcy, PhD, MS; Graduated: December 2016
Dissertation title: Exploring the an/depressant colorectal cancer association in administrative data: Negative controls, active comparators and algorithms

GRADUATED MSCR STUDENTS

1. Benjamin Wu, PharmD, MSCR; Graduated May 2020
Thesis title: Comparative Effectiveness of Primary Antimyeloma Regimens in Transplant-Ineligible Newly-Diagnosed Multiple Myeloma Medicare Beneficiaries
2. Stephanie Lumpkin, MD, MSCR; Graduated May 2020
Thesis title: Emergency Department Opioid Prescribing Variation After Discharge Following Major Surgery
3. Daniel Richardson, MD, MSCR; Graduated May 2020
Thesis title: ASXL1mutSRSF2mut Acute Myeloid Leukemia: A Rare But Distinct Subpopulation with Dismal Outcomes

CURRENT PHD STUDENTS

* Denotes MSPH/PhD student

1. Disha Subramaniam, MA; 2021-
2. Emilie Duchesneau*; 2018-
3. Christine Hsu, PharmD, MPH; 2017-
4. Charles Gaber, MPH; 2017-
5. Jeffrey Yang*; 2016-

6. Sydney Thai, MS; 2014-

CURRENT MASTER'S STUDENTS

1. Ibarido Zambrano: 2019-

POST-DOCTORAL FELLOWS

1. Michael Webster-Clark: 2019-2021
2. Jessica Islam: 2019-2021
3. Shahar Shmuel: 2020-
4. Matthew LeBlanc: 2021-

JUNIOR FACULTY MENTEES

1. Josh Niznik: Co-mentor on NIA K08 AG071794-01
Title: Deprescribing Bisphosphonates in Older Nursing Home Residents with Dementia
Role: Co-Mentor
2. Nadja Vielot: Co-mentor on NCATS UL1TR002489-03S6
Title: Effectiveness of Recombinant Herpes Zoster Vaccine in Older Adults
Role: Co-Mentor

MASTER'S COMMITTEE MEMBER

1. Nathan DeBono, MSPH (Epidemiology); Graduated: 2016
2. Jeff Yang, MSPH (Epidemiology); Graduated: 2019

DOCTORAL DISSERTATION COMMITTEE MEMBER

1. Jin Liern-Hong, PhD (Epidemiology); Graduated: 2015
2. Xin Zhou, PhD (Biostatistics); Graduated: 2015
3. Mugdha Gokhale, PhD (Epidemiology); Graduated: 2016
4. Corey Kalbaugh, PhD (Epidemiology); Graduated: 2016
5. Alan Kinlaw, PhD (Epidemiology); Graduated: 2016
6. Caitlin Murphy, PhD (Epidemiology); Graduated: 2016
7. Lynn Chollet-Hinton, PhD (Epidemiology); Graduated: 2017
8. Rebecca Naumann, PhD (Epidemiology); Graduated: 2017
9. Mihaela Georgieva, PhD (Health Policy and Management); Graduated: 2018
10. Elizabeth Garry (Epidemiology); Graduated: 2018
11. Ashley Cole (Department of Pharmaceutical Outcomes and Policy); Graduated: 2018
12. Jane Der (Epidemiology/Biostatistics); Graduated: 2019
13. Danielle Gartner (Epidemiology); Graduated: 2019
14. Chelsea Anderson (Epidemiology); Graduated: 2019
15. Liz Suarez (Epidemiology); Graduated: 2019
16. Joseph Engeda (Epidemiology); Graduated: 2019
17. Paula Strassle (Epidemiology); Graduated: 2019
18. Kristen Richetti-Masterson (Epidemiology); Graduated: 2019
19. Rachael Billock (Epidemiology); Graduated: 2020
20. Jonathan Fix (Epidemiology); May 2020 –
21. Sejin Lee (Health Policy); May 2020 –

22. Bailey DeBarmore (Epidemiology); August 2019-
23. Jihye Park (Epidemiology); April 2021-
24. Mostafa Mohamed (Epidemiology, University of Rochester); September 2021-

INTERNATIONAL VISITING SCHOLARS

1. Kathrine Lycke, BS
Department of Clinical Epidemiology, Aarhus University, Denmark; Visit: Spring 2015
Project title: Preadmission use of antidepressants and risk of complications and death after colorectal cancer surgery: A nationwide population-based cohort study
2. Anthony Matthews, MS, PhD
London School of Hygiene and Tropical Medicine, England; Visit: Spring 2018
Project title: Burden of cardiovascular disease among women age 66 and older diagnosed with non-metastatic breast cancer
3. Jakob Kirkegaard, MD
Department of Clinical Epidemiology, Aarhus University, Denmark; Visit: Spring 2018
Project title: Acute and chronic pancreatitis and the risk of pancreatic cancer: a nationwide population-based cohort study
4. Blánaid Hicks, PhD
Centre for Public Health, Queen’s University, Belfast, Northern Ireland; Visit: Fall 2018
Project title: Patterns of initiation and adherence to target therapies among older adults diagnosed with metastatic renal cell carcinoma

GRANT FUNDING

Pending

U48DP006400 (Reeder-Hayes/Baggett/Lund) 09/30/2021-9/29/2023

Creating A Stakeholder Driven Cancer Screening Surveillance Model for North Carolina Using Multi-Payer Claims Data and Small Area Estimation, total costs: \$999,084

This project proposes to develop a model cancer screening surveillance report for the state of North Carolina, using a multiple-payer insurance claims database (the Cancer Information and Population Health Resource or CIPHR) and iterative feedback from multi-lateral stakeholders involved in cancer care delivery within the state.

Role: Multiple Principal Investigator, 15% effort

Current

R21 AG068965 (Lund) 05/01/2021-04/30/2023

Improving the prediction of life expectancy among older adults with advanced cancer using geriatric assessment, total costs: \$433,055

This study will use detailed information from geriatric assessment and advanced statistical methods to develop and validate a new life expectancy prediction model for older adults (age 70 and over) with advanced cancer using geriatric assessment.

Role: Principal Investigator, 20% effort

P30 AG066615 (Frankenberg/Aiello) 07/01/2020-06/30/2025

National Institute on Aging, Carolina Center for Population Aging and Health, total costs:

\$1,800,000

Our funded pilot study will evaluate and compare the performance of contemporary screening tools to identify potentially inappropriate medications (PIMs) in older adults, document disparities in use by race/ethnicity, geography, and SES, and disentangle associations between longitudinal PIM use and important adverse health outcomes.

Role: Co-Principal Investigator, Pilot Grant (Lund/Yang), In-kind effort

R01 CA237179 (Henderson) 08/01/2020-07/31/2024

National Cancer Institute, Comorbidity and Functional Status in a Population-Based Cohort of Patients Screened for Lung Cancer, total costs: \$ 2,194,547

This study will evaluate whether risk-based lung cancer screening that incorporates pre-existing patient comorbid conditions and functional status can improve the delivery, quality, and outcomes of care in clinical practice.

Role: Co-Investigator, 10% effort

PCORI ME2017C3-9337 (Lund) 03/01/2019-01/01/2023

Patient-Centered Outcomes Research Institute, Enhancing hybrid study designs for comparative effectiveness research, total costs: \$856,230

This study will develop research tools and guidance to improve the validity and encourage the use of hybrid study designs – drawing upon both randomized clinical trial and observational data - to update what is known about the benefits and harms of a new therapy when it is used in clinical practice settings.

Role: Principal Investigator, 35% effort

FDA, BAA-19-00123-A3 (Jonsson Funk) 09/01/2019–08/31/2021

Methodological Advances in the Assessment of Uncontrolled Confounding

To develop and evaluate an array of sensitivity analyses used to assess the magnitude of uncontrolled confounding in observational studies.

Role: Co-Investigator, 10%

NIH/NIA, R01 AG056479 (Stürmer) 09/15/2017–04/30/2022

Propensity Scores and Preventive Drug Use in the Elderly

Insights into and development of different novel analytic strategies to control for selection and confounding bias in non-experimental research based on propensity scores and validation data.

Role: Co-Investigator, 10%

Past

Westat, Contract #6473-S07 (Lund) 09/15/2019–12/31/2020

Constructing Real World Evidence in Cancer Surveillance Through Data Linkage and Advanced Methods: \$30,512

To provide consulting services to the National Cancer Institute related to the uses and validity of real-world data for cancer research, related to novel linkages of cancer surveillance data to other clinical data types.

Role: Principal Investigator, 10%

NIH/NIA R01 AG050733 (Trogdon) 09/01/2016-05/31/2020

Cancer, Care Coordination, and Medication Use for Multiple Chronic Conditions, total costs: \$592,040

This study will investigate patterns of care coordination and medication use for multiple chronic conditions among older cancer patients. It will identify gaps in care coordination and medication use during cancer treatment and in the transition to survivorship and highlight the effects of policies to improve care coordination.

Role: Co-Investigator, 10% effort

NA Lund (PI) 01/01/2018-06/30/2019

Lineberger Comprehensive Cancer Center Developmental Grant: A multi-database approach to evaluating targeted therapy utilization, sequencing, and adherence in patients diagnosed with metastatic renal cell carcinoma (mRCC), total costs: \$50,000

This study will investigate the real-world utilization, sequencing, and adherence to targeted therapies for mRCC by pooling information from large healthcare databases in the United States.

Role: Principal Investigator

R21 CA191454 Lewis (PI) 01/01/2016-12/31/2018

Improving Targeted Colorectal Cancer Screening in the Elderly, total costs: \$380,288

This study uses North Carolina Medicare claims data to develop a prediction model to identify older adults who are unlikely to survive five or more years and are thus unlikely to benefit from colorectal cancer screening.

Role: Site Principal Investigator, 15% effort

NA Lund (PI) 01/01/2018-12/31/2018

IBM Junior Faculty Development Award: Investigating the effects of potential drug-chemotherapy interactions among older adults diagnosed with breast and colon cancer, total costs: \$10,000

This study will evaluate the association between concomitant hydrochlorothiazide exposure and neutropenia-related hospitalizations in: (1) breast cancer patients initiating chemotherapy containing cyclophosphamide and (2) colon cancer patients initiating chemotherapy containing 5-fluorouracil.

Role: Principal Investigator

NA Lund (PI) 01/01/2017-12/31/2017

Lineberger Comprehensive Cancer Center Developmental Grant: Generalizing colorectal cancer trial results to real world populations: A pilot study, total costs: \$50,000

This study will harness clinical trial, population-based cancer registry, and Medicare claims data to assess and apply model-based standardization for generalization of two colorectal cancer trials to target populations of patients treated in routine care. Our work in colorectal cancer will provide a framework for broader application to treatment trials from other cancer sites and generate preliminary data to support a R01-scale application to tailor the model-based standardization approach to enhance its relevance for the cancer trial setting.

Role: Principal Investigator

NIH/NCI K12 Sharpless (PI) 07/01/2015-06/30/2017

K12 Paul Calabresi Career Development Award for Clinical Oncology: Medication use, chemotherapy and adverse outcomes among older cancer patients, total direct costs: \$1,099,954

This study will use the SEER-Medicare database to describe the prevalence and outcomes of polypharmacy, potentially inappropriate medication use and medications with the potential to interact with chemotherapy among older adults initiating chemotherapy for the treatment of non-metastatic breast, colon and lung cancer or non-Hodgkin lymphoma.

Role: Trainee, 75% effort

NA Lund (PI) 07/01/2015-06/30/2017
Data@Carolina Course Development Grant: EPID 766: Epidemiologic Research Using Healthcare Databases, total costs: \$10,000

We will develop and incorporate two modules in this course that will provide students with: (1) an understanding of relational database concepts and design and how healthcare administrative utilization data can be normalized and transformed into common data models and (2) knowledge of currently available common data models.

Role: Principal Investigator

R56 AG023178 Stürmer (PI) 09/30/2015-08/31/2016
Propensity scores and preventive drug use in the elderly, total costs: \$411,862

Insights into and development of different novel analytic strategies to control for selection and confounding bias in non-experimental research based on propensity scores and validation data.

Role: Co-Investigator, 15% effort (in-kind)

NA Lund (PI) 01/01/2015-06/30/2016
PhRMA Foundation, Research Starter Award: Evaluating the heterogeneity of cancer treatment benefits among older adults, total costs: \$100,000

The goal of this study is to evaluate whether claims-based measures of multimorbidity and frailty modify the comparative effectiveness of adjuvant chemotherapy with and without oxaliplatin among older stage III colon cancer patients using the SEER-Medicare linked data.

Role: Principal Investigator, 25% effort

550KR61327 Lund, Sanoff (Co-PIs) 06/01/2014-05/31/2015
NC TraCS Pilot Award: Improved measurement of patient frailty and comorbidity for targeting subgroups of older adults in cancer comparative effectiveness research, total costs: \$50,000

This study will develop and validate claims-based measures of patient frailty and severity of comorbid disease using two data sources: the SEER-Medicare data and the Medicare Current Beneficiary Survey.

Role: Co- Principal Investigator

N/A Toft-Sorensen (PI) 03/01/2012-03/01/2013
Aarhus University, Department of Clinical Epidemiology

To validate treatment codes for identifying chemotherapy within the Danish National Patient Registry and build a national data source useful to examine patterns of cancer treatment and the comparative effectiveness and safety of treatment options in Denmark.

Role: Postdoctoral researcher

T32 DK007634 Sandler (PI) 09/01/2009-12/31/2011
Digestive Disease Epidemiology Training Grant

Primary goals: Pre-doctoral training grant to develop research skills and expertise in the area of digestive disease epidemiology and outcomes research

Role: Predoctoral trainee, 100% effort

SERVICE

Department/School/University

University of North Carolina at Chapel Hill, Department of Epidemiology Pharmacoepidemiology Faculty Search Committee Cancer Outcomes and Survivorship Faculty Search Committee	2020-
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center Cancer Information and Public Health Resource (CIPHR) Director, Data Strategy and Education	2019-
University of North Carolina at Chapel Hill, Department of Epidemiology PhD Admissions Committee, Member	2019-
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center Protocol Review Committee, Member	2016-2019
University of North Carolina at Chapel Hill, Department of Epidemiology Graduate Studies Committee, Member	2014-2018
University of North Carolina at Chapel Hill International Society of Pharmacoepidemiology (ISPE), Student Chapter Co-Chair	2009-2010
University of North Carolina at Chapel Hill Student Global Health Committee, Education Committee Chair	2008-2009
<i>National and International</i>	
International Society of Pharmacoepidemiology Board of Directors – Academic – Americas Representative	2021-
Real-World Evidence – Oncology Working Group, Core Group	2019-
Geriatric Pharmacoepidemiology Special Interest Group, Member	2018-
Education Committee, Member	2015-
Oncology Special Interest Group, Member	2013-
Comparative Effectiveness Research Special Interest Group, Member	2011-
Society of Epidemiological Research (SER) Awards Committee, Member	2018-
Education Committee, Member	2012-2016
Secretary, Student and Postdoc Committee	2009-2011
<i>Peer Review Committee – NIH, Foundations</i>	
National Cancer Institute / Office of Emergency Care Research Cancer and Emergency Medicine Research Small Group Forum	2021
V Foundation, Review Committee Robyn Roberts Thrivership Grants	2020
National Cancer Institute, Special Emphasis Panel, Study Section Member, Clinical & Translational Exploratory/Developmental Studies R21 and Omnibus R03	2018

National Institute on Aging, Invited Reviewer 2018
P01 Grant Application Reviewer

Scientific Journal Editorial Board

Pharmacoepidemiology and Drug Safety, Core Concepts, Section Editor 2020-
Pharmacoepidemiology and Drug Safety, Associate Editor 2019-
Journal of Geriatric Oncology, Editorial Board Member 2018-

Scientific Journal Peer Review

American Journal of Epidemiology
BMC Cancer
Breast Cancer Research
Cancer
Cancer Causes and Control
Cancer Epidemiology, Biomarkers, and Prevention
Cancer Medicine
Clinical Epidemiology
Epidemiology
eGEMs
Gastroenterology
Gut
Health Services Research
Inflammatory Bowel Diseases
JAMA
JAMA Network Open
Journal of the American Geriatrics Society
Journal of Cancer Research and Clinical Oncology
Journal of Clinical Epidemiology
Journal of Geriatric Oncology
Journal of the National Cancer Institute
Medical Care
Obesity
Pharmacoepidemiology and Drug Safety
The Oncologist